ArticleThe American journal of pathology2013
N,N-dimethylacetamide regulates the proinflammatory response associated with endotoxin and prevents preterm birth.
Article in The American journal of pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- The FDA-approved excipient N,N-dimethylacetamide improves survival and attenuates inflammatory pathways in a murine model of endotoxemia.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Article
- N,N-Diethylacetamide and N,N-Dipropylacetamide inhibit the NF-kB pathway in in vitro, ex vivo and in vivo models of inflammation-induced preterm birth.Scientific reports · 2025Article
- A novel modulator of IL-6R prevents inflammation-induced preterm birth and improves newborn outcome.EMBO molecular medicine · 2025Article
- Improving the safety of N,N-dimethylacetamide (DMA) as a potential treatment for preterm birth in a pregnant mouse model using a vaginal nanoformulation.Biochimica et biophysica acta. Molecular basis of disease · 2025Article
- N,N-dimethylacetamide blocks inflammation-induced preterm birth and remediates maternal systemic immune responses.Scientific reports · 2025Article
- N,N-dimethylacetamide blocks inflammation-induced preterm birth and remediates maternal systemic immune responses.bioRxiv : the preprint server for biology · 2025Article
- N,N-dimethylacetamide targets neuroinflammation in Alzheimer's disease in in-vitro and ex-vivo models.Scientific reports · 2023Article
- Vaginal Nanoformulations for the Management of Preterm Birth.Pharmaceutics · 2022Review
- Preterm Birth Therapies to Target Inflammation.Journal of clinical pharmacology · 2022Article
- New hope for preventing preterm birth: The promise of vaginal nanoformulations.Placenta and reproductive medicine · 2022Article
- Next generation strategies for preventing preterm birth.Advanced drug delivery reviews · 2021Review
- The emerging role of exosomes as novel therapeutics: Biology, technologies, clinical applications, and the next.American journal of reproductive immunology (New York, N.Y. : 1989) · 2021Review
- Exosomal delivery of NF-κB inhibitor delays LPS-induced preterm birth and modulates fetal immune cell profile in mouse models.Science advances · 2021Article
- Sodium Hydrogen Exchanger Regulatory Factor-1 (NHERF1) Regulates Fetal Membrane Inflammation.International journal of molecular sciences · 2020Article
- Erythropoietin prevents LPS-induced preterm birth and increases offspring survival.American journal of reproductive immunology (New York, N.Y. : 1989) · 2020Article
- The Release of the Bromodomain LigandMaterials (Basel, Switzerland) · 2020Article
- 17-α Hydroxyprogesterone Nanoemulsifying Preconcentrate-Loaded Vaginal Tablet: A Novel Non-Invasive Approach for the Prevention of Preterm Birth.Pharmaceutics · 2019Article
- TNF-α and IL-6 as Biomarkers of Impaired Lung Functions in Dimethylacetamide Exposure.Journal of medical biochemistry · 2019Article
- Immunobiology of Cervix Ripening.Frontiers in immunology · 2019Review
- N,N-Dimethylacetamide Significantly Attenuates LPS- and TNFα-Induced Proinflammatory Responses Via Inhibition of the Nuclear Factor Kappa B Pathway.Molecular medicine (Cambridge, Mass.) · 2016Article
Corrections and comments
- Commented on by
- Erratum issued
- Erratum issuedDosage error in article text
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
The proinflammatory response leads to various types of pathologic pathways, including the development of preterm birth. Preterm birth occurs in 12% of deliveries in the United States and causes more than 70% of perinatal morbidity and mortality. The most common cause of spontaneous preterm birth is intrauterine infection in the mother. There is accumulating evidence indicating that the release of proinflammatory cytokines plays a critical role in the pathogenesis of inflammation-associated premature delivery. We found that the common organic solvent, N,N-dimethylacetamide (DMA), prevents endotoxin-induced preterm birth in timed pregnant C57BL/6 embryonic day (E)15.5 mice and rescues their pups from spontaneous abortion at doses many-fold lower than those currently used clinically and in a dose-dependent fashion. We also provide histologic evidence that DMA suppresses the endotoxin-triggered proinflammatory response by significantly attenuating inflammatory cell infiltration of placental tissue. Furthermore, immunoblotting analysis of placental tissue harvested from our murine models revealed DMA-mediated regulation of expression of the proinflammatory cytokines IL-1β, tumor necrosis factor α, and IL-6, and increased expression of the regulatory inflammatory cytokine IL-10. By using in vitro studies, we provide evidence that DMA suppresses macrophage function and that this small molecule prevents nuclear translocation of nuclear factor-kB. These results suggest that DMA represents a newly discovered, nontoxic therapy for a broad range of inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.